Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Institute At Nationwide Children’S HospitalfiledCriticalRes Institute At Nationwide Children’S Hospital
Publication of AR118192A1publicationCriticalpatent/AR118192A1/es
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Se describen en el presente documento métodos para tratar la distrofia muscular que comprenden administrar un vector recombinante AAV (VAAr) scAAVrh74.MHCK7.hSGCB, métodos para expresar el gen del b-sarcoglicano en un paciente, composiciones farmacéuticas que comprenden el VAAr, y métodos para generar el VAAr.
ARP200100520A2019-02-262020-02-26ADMINISTRACIÓN DE b-SARCOGLICANO CON UN VECTOR DE VIRUS ADENOASOCIADO Y TRATAMIENTO DE LA DISTROFIA MUSCULAR
AR118192A1
(es)
Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута